
According to the Zhitong Finance App, Goli Pharmaceutical-B (01672) issued an announcement. Goli has submitted an ASC36_37O FDC New Drug Clinical Trial Application (IND) to the US Food and Drug Administration (FDA) to treat obesity. ASC36_37O FDC is a weekly oral fixed-dose combination (FDC) tablet of the insulin agonist polypeptide ASC36 and GLP-1R/GIPR/GCGR tri-target agonist polypeptide ASC37.
“ASC36_37O FDC is the first weekly oral fixed-dose combination to combine the four proven targets of insulin receptor, GLP-1R, GIPR, and GCGR in a single tablet.” Dr. Wu Jinzi, founder, chairman of the board of directors and CEO of Geli said, “In non-human primates, compared to what was observed in a single drug, this compound further extended the half-life of ASC36 and improved its oral bioavailability. We believe ASC36_37O FDC has the potential to provide a highly differentiated and convenient once-a-week oral treatment option for people with obesity.”
The IND submission of ASC36_37O FDC is based on recent milestones in Gli's once-a-week oral peptide pipeline. Goli has recently initiated a weekly US Phase I study on oral insulin receptor agonist polypeptide ASC36O. It is expected to obtain top-line human pharmacokinetic data for this study by the end of 2026.
Both ASC36 and ASC37 are independently developed using Golie's structure-based AI-assisted drug discovery (AISBDD) technology. ASC36_37O FDC was developed using Goli's proprietary oral peptide delivery enhancement technology (POTENT). This technology is Geli's oral peptide delivery platform. It aims to improve oral bioavailability through absorption in the stomach and intestines, and reduce pharmacokinetic (PK) differences between subjects themselves and subjects.
In non-human primates, the half-lives of ASC36 and ASC37 in ASC36_37O FDC were as long as 200 hours (about 8.3 days) and 96 hours (4 days), respectively, and oral bioavailability was > 10% and ≥ 9.1%, respectively. After combining the two peptides into a single tablet, the half-life of ASC36 was extended from about 7 days with a single drug (ASC36o) to about 8.3 days, and oral bioavailability increased from 6% to 8% as a single agent to > 10% in fixed-dose compound formulations.
In a study on obesity induced by a head-to-head diet, the combined formulation of ASC36 and ASC37 improved the weight loss effect of ASC37 alone by about 69%, and the weight loss effect of ASC36 alone was about 192% higher than that of ASC36 alone.